2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infection
2020
Correction to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Correction to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 3140-3140. PMID: 33021712, PMCID: PMC7572953, DOI: 10.1007/s11606-020-06227-w.Peer-Reviewed Original ResearchExcess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohort
2017
DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty
Zhang X, Hu Y, Justice AC, Li B, Wang Z, Zhao H, Krystal JH, Xu K. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. Nature Communications 2017, 8: 2243. PMID: 29269866, PMCID: PMC5740109, DOI: 10.1038/s41467-017-02326-1.Peer-Reviewed Original ResearchConceptsIllicit drug injectionHepatitis C infectionWhite blood cellsIllicit drug useCo-occurring conditionsMethylation signaturesDiscovery sampleC infectionHepatitis CEpigenome-wide association analysisLower frailtyDrug injectionHigh frailtyImmune functionHealth outcomesDrug useFrailtyDNA methylation signaturesBlood cellsHIVReplication sampleEpigenetic programmingSignificant CpGsEpigenetic effectsIndividuals
2016
Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients
McGinnis KA, Tate JP, Williams EC, Skanderson M, Bryant KJ, Gordon AJ, Kraemer KL, Maisto SA, Crystal S, Fiellin DA, Justice AC. Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients. Drug And Alcohol Dependence 2016, 168: 196-202. PMID: 27694059, PMCID: PMC5086273, DOI: 10.1016/j.drugalcdep.2016.09.015.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useVeterans Aging Cohort StudyAlcohol useClinical screeningElectronic medical record dataHepatitis C infectionAging Cohort StudyMedical record dataElectronic medical recordsUninfected womenC infectionUninfected menUninfected patientsCohort studyMedical recordsUninfected individualsClinical decisionHIVModerate agreementRecord dataEMR dataMenAssess agreementWomenEMRHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infectionRisk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men
Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, Edelman EJ, Fiellin LE, Freiberg MS, Gordon AJ, Kraemer KL, Marshall BD, Williams EC, Fiellin DA. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug And Alcohol Dependence 2016, 161: 95-103. PMID: 26861883, PMCID: PMC4792710, DOI: 10.1016/j.drugalcdep.2016.01.017.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyRisk of mortalityAUDIT-C scoresUninfected individualsPhysiologic injuryAlcohol exposureUndetectable HIV-1 RNACox proportional hazards modelAlcohol useVACS Index scoreHepatitis C infectionAging Cohort StudyHIV-1 RNAProportional hazards modelAlcohol consumption limitsLow alcohol exposureAlcohol-related harmRace/ethnicityAntiretroviral therapyC infectionUninfected menCohort studyHIV statusHazards modelIndex score
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete data
2012
Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States
Ohl ME, Perencevich E, McInnes DK, Kim N, Rimland D, Akgun K, Fiellin DA, Skanderson M, Wang K, Justice A. Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States. AIDS And Behavior 2012, 17: 174-180. PMID: 23080359, DOI: 10.1007/s10461-012-0325-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsConfidence IntervalsFemaleFollow-Up StudiesHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedOdds RatioResidence CharacteristicsRetrospective StudiesRural PopulationSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransConceptsRural-dwelling personsAntiretroviral therapyAntiretroviral adherenceUrban veteransRural-Urban Commuting Area codesVeterans Affairs Healthcare SystemCombination antiretroviral therapyHepatitis C infectionMultivariable logistic regressionSubstance use disordersC infectionHIV infectionRemote residentsHigh adherenceWhite raceVA healthcareUse disordersMedian proportionLogistic regressionAdherenceHealthcare systemRemote settingsTherapyInfectionFace barriers
2006
Hepatocellular Carcinoma and Non-Hodgkin's Lymphoma: The Roles of HIV, Hepatitis C Infection, and Alcohol Abuse
McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular Carcinoma and Non-Hodgkin's Lymphoma: The Roles of HIV, Hepatitis C Infection, and Alcohol Abuse. Journal Of Clinical Oncology 2006, 24: 5005-5009. PMID: 17075119, DOI: 10.1200/jco.2006.05.7984.Peer-Reviewed Original ResearchConceptsAlcohol abuse/dependenceHIV-negative veteransAbuse/dependenceHIV-positive veteransIncident rate ratiosHepatocellular carcinomaGreater riskVeterans Affairs Healthcare SystemFirst HIV diagnosisHepatitis C infectionPresence of HCVRole of HIVNinth Revision codesNon-Hodgkin lymphomaRelationship of HIVHeavy alcohol useHigher relative incidencePoisson regression modelsC infectionHCV infectionHepatitis CHIV diagnosisHIV statusHodgkin's lymphomaRevision codes